针对自的NBR1-p62/SQSTM1复合体通过隔离ITCH促进乳腺癌转移
Gourish Mondal1, Hugo Gonzalez2,3, Timothy Marsh1
1Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
Nature cell biology
|June 27, 2025
概括
乳腺癌的自缺陷通过积累NBR1和p62/SQSTM1载荷受体驱动转移. 这些复合物稳定p63,促进基底分化和瘤扩散.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
背景情况:
- 自在细胞蛋白质稳定中起着至关重要的作用,并与癌症进展有关.
- 自的缺陷越来越被认为是癌症转移的驱动因素.
- 载荷受体NBR1和p62/SQSTM1是自途径的关键组成部分.
研究的目的:
- 阐明自性缺陷在乳腺癌转移中的作用.
- 研究NBR1和p62/SQSTM1积累促进转移的机制.
- 确定抑制自驱动乳腺癌进展的治疗点.
主要方法:
- 利用了小鼠和人类乳腺癌模型.
- 研究了NBR1-p62/SQSTM1生物分子凝聚物的形成.
- 评估了NBR1-p62/SQSTM1复合体,ITCH和p63.3之间的相互作用.
- 研究了突变NBR1对体内转移的影响.
主要成果:
- 自缺乏导致乳腺癌细胞中NBR1和p62/SQSTM1载荷受体的积累.
- 累积的NBR1-p62/SQSTM1复合体隔离了无素结合酶ITCH,稳定了前转移因子p63.
- 这种p63的稳定驱动基底分化,并在小鼠和人类模型中促进转移.
- 不能隔离ITCH的突变NBR1取消了这些转移前效应.
结论:
- 乳腺癌中自抑制通过NBR1-p62/SQSTM1复合体形成和p63稳定促进转移.
- 治疗性抑制自会导致蛋白质静止缺陷,从而增强乳腺癌的转移潜力.
- 针对这些NBR1-p62/SQSTM1-ITCH-p63轴相互作用可能为乳腺癌提供新的治疗策略.
更多相关视频
07:35A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
41.5K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.8K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265
